Combinatorial Effect of Ing4 and Trail Gene Expressing Oncolytic Adenoviruses in Hepatocellular Carcinoma Combinatorial Effect of Ing4 and Trail Gene Expressing Oncolytic Adenoviruses in Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Eonju | - |
dc.contributor.author | Jung, Bo-Kyeong | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2021-08-02T13:30:22Z | - |
dc.date.available | 2021-08-02T13:30:22Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/17014 | - |
dc.description.abstract | Current treatments of hepatocellular carcinoma (HCC) are ineffective and unsatisfactory in many aspects. Cancer-targeting gene virotherapy using oncolytic adenoviruses (OAds) armed with anticancer genes has shown efficacy and safety in clinical trials. Nowadays, both inhibitor of growth 4 (ING4); as a multimodal tumor suppressor gene, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); as potent-apoptosis inducing gene, are experiencing a renaissance in cancer gene therapy. Herein we investigated the antitumor activity and safety of mono-and combined therapy with OAds armed with ING4 (Ad-ΔB/ING4) and TRAIL (Ad-ΔB/TRAIL) gene, respectively, on preclinical models of human HCC. OAd-mediated expression of ING4 or TRAIL transgene was confirmed. Ad-ΔB/TRAIL and/or Ad-ΔB/ING4 exhibited potent killing effect on human HCC cells (HuH7 and Hep3B) but not on normal liver cells. Most importantly, systemic therapy with Ad-ΔB/ING4 plus Ad-ΔB/TRAIL elicited more eradicative effect on an orthotopic mouse model of human HCC than their monotherapy, without causing obvious overlapping toxicity. Mechanistically, Ad-ΔB/ING4 and Ad-ΔB/TRAIL were remarkably cooperated to induce anti-tumor apoptosis and immune response, and to repress tumor angiogenesis. This is the first study showing that concomitant therapy with Ad-ΔB/ING4 and Ad-ΔB/TRAIL may provide a potential strategy for HCC therapy and merits further investigations to realize its possible clinical translation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | CELL PRESS | - |
dc.title | Combinatorial Effect of Ing4 and Trail Gene Expressing Oncolytic Adenoviruses in Hepatocellular Carcinoma Combinatorial Effect of Ing4 and Trail Gene Expressing Oncolytic Adenoviruses in Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.1016/j.ymthe.2018.05.001 | - |
dc.identifier.wosid | 000435342204151 | - |
dc.identifier.bibliographicCitation | MOLECULAR THERAPY, v.26, no.5, pp.332 - 332 | - |
dc.relation.isPartOf | MOLECULAR THERAPY | - |
dc.citation.title | MOLECULAR THERAPY | - |
dc.citation.volume | 26 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 332 | - |
dc.citation.endPage | 332 | - |
dc.type.rims | ART | - |
dc.type.docType | Meeting Abstract | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine | - |
dc.relation.journalWebOfScienceCategory | Research & Experimental | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1525001618302041?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.